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sUMMARy – Recent evidence suggests that lower HDL-cholesterol (HDL-C) may worsen 
the atherosclerotic process by promoting inflammation and progression from subclinical lesion to 
clinical event. Carotid intima-media thickness (CiMt) is recognized as a marker of early atherosc-
lerosis and used to predict future vascular events. Among the common lipid parameters, LDL has 
strongest relation with carotid plaque. Cumulative effect of achieving optimal levels of LDL-C, 
HDL-C, triglycerides and blood pressure is a reduced risk of recurrent stroke and major cardiovas-
cular events. The protective effect of higher HDL-C is maintained at low levels of LDL-C. studies 
have demonstrated a trend toward a higher risk of stroke with lower HDL-C and support HDL-C 
as an important modifiable stroke risk factor. in patients with recent stroke or transient ischemic 
attack and no coronary heart disease, only lower baseline HDL-C predicted the risk of recurrent 
stroke. substantial amount of residual cardiovascular risk remains in patients treated with statins 
due to elevated triglycerides and low HDL-C, even when LDL-C is well controlled. niacin pro-
motes significant increase in HDL-C and reduces cardiovascular risk. by combining niacin with 
the LDL-lowering therapy of statins, the progression of atherosclerosis is slowed down and residual 
cardiovascular and risk of stroke is reduced. non-pharmacological control of serum lipids includes 
regular physical activity and modification in daily diet. in primary prevention, when HDL-C is be-
low the average and other risk factors are present, a statin added to non-pharmacological therapy is 
appropriate choice. Fibrate therapy may be appropriate in men with manifest coronary disease with 
isolated low HDL-C. if HDL-C remains low, with or without high triglyceride levels, a fibrate or 
niacin may be added.
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High-Density Lipoprotein Cholesterol and Risk of 
Ischemic Stroke and Cardiovascular Events
Low HDL-cholesterol (HDL-C) concentrations 
are associated with an increased cardiovascular risk 
and may aggravate the atherosclerotic process by pro-
moting inflammation. Lower HDL-C levels may po-
tentially accelerate the progression from subclinical 
lesions to cardiovascular clinical events. Carotid in-
tima-media thickness (CiMt) is used as a marker of 
early atherosclerosis that significantly correlates with 
the presence of coronary artery disease and is able to 
predict future cardio- and cerebrovascular (CV) events 
in patients with subclinical carotid atherosclerosis. An 
updated view of the HDL-C has shown that the mac-
rophage scavenger receptor bi (sR-bi) plays an inte-
gral role in the catabolism of HDL-C. Up-regulation 
of this receptor reduces plaque formation in an LDL-
receptor-deficient mouse model of atherosclerosis. 
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phospholipid transfer protein has also become a target 
of increased analysis, as its role in the maturation of the 
HDL particle has become better understood. In vitro 
data from a transgenic mouse model over-expressing 
this protein demonstrate that plasma from these ani-
mals exhibits a potentially anti-atherogenic reduction 
in macrophage uptake of cholesterol. over-expression 
of phospholipid transfer protein also yielded substan-
tial reductions in HDL-C. These decreases combined 
with diminished atherogenicity imply more efficient 
reverse cholesterol transport, perhaps through the en-
hanced generation of pre-beta HDL38-40.
Prediction of Cardio- and Cerebrovascular Events 
in Patients with Subclinical Carotid Atherosclerosis 
and Low HDL-cholesterol
prediction of cardio- and cerebrovascular events 
was assessed in patients with subclinical carotid ath-
erosclerosis and low HDL-cholesterol. Results showed 
that lower HDL-C concentrations were associated 
with ischemic stroke, peripheral arterial disease or 
with the presence of any clinical event. independent 
variables associated with the events with predictive 
role were elevated fibrinogen concentrations, family 
history of coronary artery disease, and lower HDL-C 
levels. These results further suggest a synergistic role 
of low-HDL-C and inflammation in the atheroscle-
rotic disease progression from subclinical lesions to 
clinical events1. A low level of HDL-C has been iden-
tified as a risk factor for stroke. Reduction in stroke 
with gemfibrozil therapy in men with coronary heart 
disease and low HDL-C has been observed in The 
Veterans Affairs HDL intervention trial (VA-Hit). 
The trial objective was to determine whether treatment 
aimed at raising HDL-C and lowering triglycerides 
reduces stroke in men with coronary heart disease and 
low levels of both HDL and LDL-C. A total of 2531 
men with coronary heart disease, with mean HDL-
C 31.5 mg/dL and mean LDL-C 111 mg/dL, were 
randomized to gemfibrozil 1200 mg/d or placebo and 
followed up for 5 years. in the placebo group, there 
were 76 strokes (9 fatal) and in the gemfibrozil group 
58 strokes (3 fatal). Relative risk reduction by 31% was 
observed and evident after 6 to 12 months in the gem-
fibrozil group. patients with baseline HDL-C below 
the median may have been more likely to benefit from 
gemfibrozil treatment than those with higher HDL-
C2. Lipoprotein-associated phospholipase A2 (Lp-
pLA2) is a proinflammatory enzyme that can predict 
major cardiovascular events, independent of both tra-
ditional risk factors and other markers of inflamma-
tion. in plasma, Lp-pLA2 is predominantly bound to 
LDL, and higher activity levels of this enzyme are es-
pecially associated with small-size LDL particles that 
are more atherogenic than larger LDL particles. Lp-
pLA2 is also associated with HDL and may migrate 
between LDL and HDL particles in the circulation. 
in contrast to the positive association of Lp-pLA2 
with LDL, this particular phospholipase has been 
found to be negatively correlated with plasma HDL-
C concentrations, suggesting that higher levels of Lp-
pLA2 might especially be associated with proathero-
genic processes that are predominantly associated 
with lower levels of HDL-C. Lipoprotein-associated 
phospholipase A2 has been shown in general popula-
tions to predict cardiovascular events. increased Lp-
pLA2 could predict CV events in the absence of high 
LDL-C, in a population with low HDL-C. plasma 
Lp-pLA2 activity was measured at baseline and af-
ter 6 months in a study group of 1451 men with low 
HDL-C (32 mg/dL) and low LDL-C (110 mg/dL), 
randomized to either placebo or gemfibrozil therapy. 
After adjustment for major CV risk factors, a 1-sD in-
crease in Lp-pLA2 was associated with a significant 
increase in cardiovascular events (HR 1.17). Although 
gemfibrozil reduced Lp-pLA2 only modestly (6.6%), 
at higher levels of Lp-pLA2 gemfibrozil produced 
a significant reduction in CV events. in VA-Hit, a 
population with low HDL-C and LDL-C, high Lp-
pLA2 independently predicted CV events that were 
reduced by gemfibrozil3. Reduced serum HDL-C is 
also an independent risk factor for ischemic stroke in 
elderly men. A significant temporal and quantitative 
relationship was observed between HDL-C levels 
and acute ischemic stroke presentation in the study 
that included 191 patients with first ever acute isch-
emic stroke. The average HDL-C at presentation was 
44.4 mg/dL. patients with a history of diabetes mel-
litus had lower HDL-C levels than non-diabetics at 
the time of stroke admission. traditional stroke risk 
factors (dyslipidemia, diabetes mellitus, hypertension, 
tobacco use, coronary artery disease, and myocardial 
infarction) were inversely associated with HDL-C 
levels. HDL-C decreased from pre-stroke (55.0 mg/
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dL) to immediate post-stroke levels (44.4 mg/dL) by 
18.1%. HDL-C levels increased between immediate 
post-stroke levels and follow-up testing (51.6 mg/dL) 
after 2.6 months by an average of 29.6%.  prior his-
tory of myocardial infarction diminished HDL-C de-
pression at the time of stroke. Findings indicated that 
HDL-C may be an acute phase reactant or nascent 
biomarker of acute stroke susceptibility4.
Association of Lipid Profile with Ischemic Stroke
Association of lipid profile with ischemic stroke 
was evaluated in the observational case control study. 
The relation of ischemic stroke with different compo-
nents of serum lipids showed that ischemic stroke was 
more common after age 50. Male suffered more than 
female from ischemic stroke (male to female ratio = 
2.57:1). Hypertension and diabetes mellitus were 
found to be significant risk factors for ischemic stroke. 
High level of serum total cholesterol and LDL-C 
showed a significant risk in ischemic stroke. Low lev-
el of HDL-C appeared as a significant risk factor in-
dicating beneficial effect of HDL-C on atheroscle-
rotic process. serum triglyceride level showed no 
significant effect on ischemic stroke5. The influence of 
total cholesterol, HDL-C and triglycerides on the risk 
of cerebrovascular disease was evaluated in the Co-
penhagen City Heart study. total cholesterol was 
positively associated with the risk of non-hemorrhagic 
events, but only for levels >8 mmol/L, while the rela-
tive risk remained nearly constant for lower plasma 
cholesterol values. plasma triglyceride concentration 
was significantly positively associated with the risk of 
non-hemorrhagic events. There was a negative log lin-
ear association between HDL-C and risk of non-
hemorrhagic events6. High-density lipoprotein cho-
lesterol and the risk of ischemic stroke mortality was 
evaluated during 21-year follow-up of 8586 men from 
the israeli ischemic Heart Disease study. During the 
follow-up, 295 men died from cerebrovascular events 
(241 due to ischemic stroke). individuals with fatal 
ischemic stroke had a marginally lower age-adjusted 
mean HDL-C (1.05 mmol/L) and a significantly low-
er age-adjusted mean percentage of serum cholesterol 
contained in the HDL fraction (19.3%) than counter-
parts surviving the follow-up period (1.06 mmol/L 
and 20.6%, respectively). in multivariate analysis, a 
low concentration of HDL-C appeared to be signifi-
cantly predictive of ischemic stroke mortality7. The 
northern Manhattan stroke study analyzed HDL-C 
and ischemic stroke in the elderly. The protective ef-
fect of a higher HDL-C level was significant among 
participants aged 75 or older and more potent for the 
atherosclerotic stroke subtype and among different ra-
cial or ethnic groups. HDL-C is an important modi-
fiable stroke risk factor8. Different risk factors for dif-
ferent stroke subtypes and association of cholesterol 
showed that serum total cholesterol was inversely as-
sociated with the risk of intracerebral hemorrhage, 
whereas the risk of cerebral infarction was raised at 
concentrations ≥7.0 mmol/L. The risks of subarach-
noid hemorrhage and cerebral infarction were lowered 
with serum HDL-C levels ≥0.85 mmol/L9. Associa-
tion of cholesterol with stroke risk varies in stroke 
subtypes and patient subgroups. Higher total and 
lower HDL-C levels were associated with an in-
creased risk of ischemic stroke, especially certain 
stroke subtypes. The lowest levels of total cholesterol 
were associated with an increased risk of all hemor-
rhagic strokes10. HDL-C, total cholesterol, and the 
risk of stroke were analyzed in middle-aged british 
men; higher levels of HDL-C were associated with a 
significant decrease in the risk of nonfatal stroke. in 
contrast, elevated total cholesterol showed a weak 
positive association with nonfatal strokes. The marked 
inverse association between HDL-C and stroke seen 
in hypertensives emphasizes the importance of these 
modifiable risk factors for stroke. The beneficial ef-
fects of elevated HDL-C on nonfatal stroke were seen 
in both smokers and nonsmokers and were more evi-
dent in men with hypertension than in normoten-
sives11. Relative contributions of baseline systolic and 
diastolic blood pressure, low- and high-density lipo-
proteins and triglycerides to the risk of recurrent 
stroke or first major cardiovascular event (MCVe) 
and their potential impact on the benefit of statin 
treatment were evaluated in the stroke prevention by 
Aggressive Reduction in Cholesterol Levels (spAR-
CL) trial. The spARCL trial randomized 4731 pa-
tients with recent stroke or transient ischemic attack 
(tiA) and no known coronary heart disease and 
LDL-C between 100 and 190 mg/dL to either ator-
vastatin 80 mg/d or placebo. After 4.9 years of follow-
up, there were 575 primary end points (fatal and non-
fatal stroke), including 491 ischemic strokes, and 740 
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MCVes (stroke plus myocardial infarction and vas-
cular death). in patients with recent stroke or tiA 
and no coronary heart disease, only lower baseline 
HDL-C predicted the risk of recurrent stroke. base-
line HDL-C, triglycerides, and LDL/HDL ratio 
were associated with MCVe. only baseline HDL-C 
and LDL/HDL ratio were associated with an out-
come ischemic stroke. each 13.7 mg/dL increment in 
HDL-C was associated with a 13% reduction in the 
risk of ischemic stroke and each doubling of LDL/
HDL ratio was associated with a 31% increase in the 
risk of ischemic stroke. Atorvastatin treatment was 
similarly effective regardless of baseline lipoprotein 
levels12. Relative and cumulative effect of lipid and 
blood pressure (bp) control was further analyzed in 
the stroke prevention by Aggressive Reduction in 
Cholesterol Levels trial (spARCL). There were 4731 
patients with recent stroke or transient ischemic at-
tack and no known coronary heart disease random-
ized to atorvastatin 80 mg per day or placebo. At each 
level of LDL-C reduction, subjects with HDL-C 
value above the median or systolic bp below the me-
dian had greater reductions in stroke and major car-
diovascular events, and those with a reduction in trig-
lycerides above the median or diastolic bp below the 
median showed similar trends. optimal control was 
defined as LDL-C 70 mg/dL, HDL-C 50 mg/dL, 
triglycerides 150 mg/dL, and sbp/Dbp 120/80 mm 
Hg. The risk of stroke decreased as the level of control 
increased in those achieving optimal control of 1, 2, 3 
or 4 factors as compared to none. Results were similar 
for major cardiovascular events. Cumulative effect of 
achieving optimal levels of LDL-C, HDL-C, triglyc-
erides and bp on the risk of recurrent stroke and ma-
jor cardiovascular events was observed. optimal con-
trol of LDL-C (70 mg/dL), triglycerides (150 mg/dL), 
bp (120/80 mm Hg) and having an HDL-C value 
above 50 mg/dL had a cumulative effect on reducing 
stroke and major cardiovascular events, with hazard 
ratios decreasing as optimal levels of 1, 2, 3 or 4 of 
these factors were achieved (P=0.0012 for stroke and 
P=0.0001 for major cardiovascular events). The pro-
tective effect of having a higher HDL-C was main-
tained at low levels of LDL-C13. in the cross-section-
al study of 324 apparently healthy Japanese men, high 
levels of serum cholesterol and the risk of stroke were 
analyzed. t1-weighted, t2-weighted and FLAiR 
MR images were used to detect and discriminate si-
lent brain infarcts (sbi). serum cholesterol was sig-
nificantly associated with sbi: total cholesterol-odds 
ratio (oR) 3.75; LDL-C, oR 2.54, and non-HDL 
cholesterol, oR 2.54. There was a tendency for a posi-
tive association of HDL-C with sbi after adjustment 
for age, smoking status, serum triglycerides, maximal 
iMt, obesity, hypertension, diabetes mellitus, hype-
ruricemia, coronary heart disease and lipid-lowering 
agent use. serum cholesterol levels are associated with 
sbi independently of the known confounders14. Vas-
cular cognitive impairment is an important cause of 
cognitive decline in the elderly. Vascular dementia can 
be caused by small-vessel disease (s-VaD) or by large-
artery atherosclerosis with multi-infarct vascular le-
sions in strategic areas of the brain (M-VaD). Vascular 
and biochemical risk factors of vascular dementia after 
lacunar strokes (s-VaD) and after multi-infarcts in 
strategic areas (M-VaD) were evaluated in patients 
with both types of dementia. in 60 patients with s-
VaD and 34 patients with M-VaD, the presence of 
vascular and biochemical risk factors was evaluated 
and compared to age- and sex-matched 126 controls 
without dementia. Coronary artery disease, atrial fi-
brillation, hypertension and strokes were observed 
more frequently in both groups. of biochemical risk 
factors, hyperhomocysteinemia (associated with low 
levels of folic acid and vitamin b12) and low HDL-C 
levels were found in both forms of VaD15.
The Role of HDL Cholesterol in Metabolic Syndrome 
Predicting Cardiovascular Events
evaluation of differences in the levels of serum 
atherosclerotic and fibrinolytic markers and the prev-
alence of metabolic syndrome was performed among 
patients with subtypes of cerebral infarctions. blood 
samples from 171 cerebral infarction patients were 
collected to determine the levels of high-sensitivity 
C-reactive protein, serum total homocysteine, serum 
plasminogen activator inhibitor 1 and lipoprotein A. 
subjects were also screened for metabolic syndrome. 
Atherothrombotic infarction was most prevalent, fol-
lowed by lacunar and embolic infarction. There were 
no statistically significant differences in serum marker 
concentrations. The proportion of metabolic syn-
drome varied significantly among the subtypes and 
was highest among patients with embolic infarctions 
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with the lowest HDL-C levels16. HDL cholesterol in 
metabolic syndrome can predict cardiovascular events. 
Metabolic syndrome has recently been claimed to be 
an important new risk factor for the occurrence of 
coronary heart disease (CHD) and cardiovascular 
disease (CVD) events. Analysis of the predictive role 
of metabolic syndrome for CHD and CVD events 
was performed in a population study using the same 
factors in a continuous fashion, with special emphasis 
on HDL-C. There were 2650 cardiovascular disease-
free men and women aged 35-74 years, examined and 
followed-up for 12 years. The classic risk factors (sex, 
age, systolic blood pressure, serum cholesterol and 
smoking habits) were studied as predictors of CHD 
and CVD events, alone and with the contribution of 
other factors (HDL-C, blood glucose, serum triglyc-
erides and waist circumference) included in metabolic 
syndrome. Metabolic syndrome produced a predictive 
significant relative risk of 1.67 for CHD events and 
1.82 for CVD events, but considering its single risk 
factors, the only ones contributing to the prediction 
were HDL-C and systolic blood pressure. Analyses 
showed that metabolic syndrome did not add anything 
to the power of prediction beyond the role of the single 
risk factors treated in a continuous fashion, while the 
best predictive power was obtained using classic risk 
factors (sex, age, smoking habits, total cholesterol and 
systolic blood pressure) with the addition of HDL-C. 
The correlation coefficient between total and HDL-C 
was modest and this justifies the contemporary pres-
ence in the models of these two variables and presen-
tation of the relationship between HDL-C and CHD 
or CVD risk for different levels of total cholesterol. 
At each level of total cholesterol, increasing values of 
HDL-C correspond to a declining CHD and CVD 
risk. The predictive power of metabolic syndrome is 
bound only to the presence of HDL-C and blood pres-
sure and does not add anything to using the same risk 
factor treated in a continuous fashion17. Lipids and ca-
rotid plaque were assessed in the northern Manhat-
tan study. Cross-sectional analysis to investigate the 
relation between blood lipids and carotid plaque and 
to determine the incidence and risk factors of stroke 
was performed in a multiethnic population with lipid 
measurements and b-mode ultrasound of carotid ar-
teries. plaque was present in 61% of the participants 
and the mean total cholesterol was 202±41 mg/dL. 
Multiple logistic regression results showed that only 
LDL-C was associated with carotid plaque. neither 
HDL-C nor triglycerides independently predicted 
carotid plaque. Apolipoprotein b (Apob) was asso-
ciated with the risk of plaque, while apolipoprotein 
A1 (apoA1) was associated with a decrease in multiple 
plaques. Lipoprotein-A was associated with an in-
creased risk of multiple plaques. The apob/apoA1 ra-
tio had strongest relation with carotid plaque. Among 
the common lipid parameters, LDL-C has strongest 
relation with carotid plaque. Apob and apoA1 may be 
stronger predictors of subclinical atherosclerosis and 
better targets for treatment to reduce plaque forma-
tion and risk of CVD18.
Dyslipidemia among Diabetic Patients with Ischemic 
Stroke
Dyslipidemia is a potential independent risk factor 
for cerebrovascular disease in patients with diabetes. 
A total of 1046 patients with type 2 diabetes were 
assigned to diabetes with stroke and diabetes with-
out stroke groups. Diabetic patients suffering stroke 
displayed poorly-controlled lipid and lipoprotein 
profiles, including a significantly lower proportion of 
patients achieving intensified LDL-C target of <2.07 
mmol/L, but also less adherence to therapy prescribed 
for dyslipidemia, when compared with diabetic pa-
tients without stroke. Diabetic women with stroke 
had significantly lower serum level of HDL-C and 
apoA1, higher LDL-C level and higher apob/apoA1 
ratio when compared with diabetics without stroke. 
Diabetic patients with ischemic stroke remained un-
controlled for dyslipidemia. intensified LDL-C and 
overall lipid lowering are potential precautions taken 
against ischemic stroke among diabetic patients. For 
LDL-C, no significant difference between diabetic 
patients with and without stroke (47.5% vs. 43.9%, 
P=0.236) was found in the proportion of subjects who 
were controlled for LDL-C <2.6 mmol/L. For HDL-
C, a significantly smaller proportion of diabetic sub-
jects with ischemic stroke had HDL-C levels >1.0 
mmol/L for men and >1.3 mmol/L for women. More-
over, the likelihood of triglycerides being controlled 
to <1.7 mmol/L was not significant in those with 
ischemic stroke (74.4%) compared with those without 
ischemic stroke (72.4%)19. The efficacy of cholesterol-
lowering therapy in 18,686 people with diabetes in 
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14 randomized trials of statins was evaluated in the 
meta-analysis performed by the Cholesterol treat-
ment trialists’ Collaborators. both types of diabetes 
are associated with dyslipidemia. in type 2 diabetes, 
triglyceride concentrations are high but HDL-C con-
centrations tend to be low, whereas in type 1 diabetes 
triglyceride concentrations are generally lower than 
those in type 2 diabetes, and HDL-C levels are av-
erage or even high. in both diseases, the concentra-
tion of LDL-C in the blood is generally similar to the 
population average, although this apparently benign 
pattern can mask an increase in atherogenic small 
dense LDL particles. Results of a collaborative me-
ta-analysis of 14 randomized trials of statin therapy 
showed that lowering LDL cholesterol by 1 mmol/L 
reduces the risk of major vascular events (defined as 
the composite outcome of myocardial infarction or 
coronary death, stroke, or coronary revascularization) 
by about one-fifth in a wide range of high-risk partici-
pants, largely irrespective of baseline lipid profile or 
other presenting characteristics including diabetes20. 
evaluation of the atherogenicity of lipids with nor-
mal fasting glucose (nFg), impaired fasting glucose 
(iFg), and type 2 diabetes was performed in coronary 
patients. triglycerides significantly increased, while 
HDL-C and LDL particle diameter significantly 
decreased from subjects with nFg 5.6 mmol/L over 
patients with iFg 5.6 mmol/L to patients with type 
2 diabetes. Factor analysis revealed several factors in 
the patient lipid profiles, i.e. triglycerides, HDL-C, 
apoA1, and LDL particle diameter loaded high on an 
HDL-related factor, and total cholesterol, LDL-C, 
and apob loaded high on an LDL-related factor. in 
patients with type 2 diabetes, the HDL-related fac-
tor was associated with significant coronary stenoses 
of 50%. Consistently, in the prospective study, the 
HDL-related factor but not the LDL-related fac-
tor proved significantly predictive for vascular events 
in patients with type 2 diabetes. The low HDL-C/
high triglyceride pattern is associated with the degree 
of hyperglycemia. in coronary patients with type 2 
diabetes, this pattern correlates with the prevalence 
of CAD and significantly predicts the incidence of 
vascular events. For all 750 patients, triglycerides 
steadily increased, while HDL-C and LDL peak 
particle diameter steadily and significantly decreased 
from patients with nFg, over patients with iFg, 
to patients with type 2 diabetes. specific treatment 
of diabetic dyslipidemia is most promising to reduce 
cardiovascular events among patients with diabetes. 
with well tolerated extended-release formulations of 
niacin, it is now possible to improve the pattern of 
lipid abnormalities observed in patients with type 2 
diabetes. inhibition of cholesterol ester transfer pro-
tein activity with torcetrapib has recently been shown 
to increase HDL-C by as much as 106%21. glycemic 
index is a determinant of serum HDL-C concentra-
tion. Diet influences the prevalence of coronary heart 
disease and insulin sensitivity and concentrations of 
HDL-C. Dietary carbohydrates with a high glycemic 
index cause a high postprandial glucose and insulin 
response, and are associated with decreased insulin 
sensitivity and an increased risk of CHD. is the gly-
cemic index of dietary carbohydrates a determinant 
of serum HDL-C concentrations? Dietary, anthropo-
metric and biochemical data from the survey of brit-
ish Adults were reanalyzed by a multiple regression 
model and examined the relation between serum total 
cholesterol, HDL-C and calculated LDL-C concen-
trations and various dietary characteristics including 
the type of carbohydrate, the glycemic index, and fat 
intake. Among 1420 participants with complete data, 
there was a significant negative relation between se-
rum HDL-C concentration and the glycemic index 
of the diet for both men and women. no other sig-
nificant relation was found with total cholesterol or 
LDL-C concentration or with any other dietary car-
bohydrate or fat constituent. in a cross-sectional study 
of middle-aged adults, the glycemic index of the diet 
was the only dietary variable significantly related to 
serum HDL-C concentration. Thus, the glycemic in-
dex of the diet is a stronger predictor than dietary fat 
intake of serum HDL-C concentration22.
Targeting Low HDL-Cholesterol to Decrease 
Residual Cardiovascular Risk
several large trials and meta-analyses have consis-
tently demonstrated that statin therapy significantly 
reduces LDL-C levels and incidence of cardiovascular 
events. in spite of the efficacy of statin therapy, sta-
tins do not eliminate cardiovascular risk completely. 
significant residual cardiovascular risk remains after 
treatment with statins, especially in high-risk patients 
such as those with diabetes. Residual cardiovascular 
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risk stems partially from low HDL-C and elevated 
triglycerides. Low HDL-C levels have been identified 
as a significant, independent predictor of cardiovascu-
lar risk, and increases in HDL-C are associated with 
reductions in cardiovascular events. Low HDL-C is 
associated with high cardiovascular risk. The tnt 
trial investigated the efficacy of high-dose statin ther-
apy compared with low-dose statin therapy in patients 
with stable CHD. patients were randomized to receive 
either atorvastatin (80 mg) with a target LDL-C of 70 
mg/dL, or atorvastatin (10 mg) with a target LDL-C 
of 100 mg/dL. patients with lower LDL-C levels had 
an approximate 25% risk reduction of having a CHD 
event. if subjects had low LDL-C levels, they still 
had a very high rate of CHD events if they also had 
low HDL-C levels. with higher HDL-C levels, the 
CHD rate decreased significantly. even for patients 
in the lowest stratum of LDL-C (≤70 mg/dL) after 
3 months of statin treatment, there was an increased 
5-year risk of major cardiovascular events if HDL-C 
levels were also low. The risk of a major cardiovas-
cular event differed significantly among quintiles of 
HDL-C levels in which those patients in the highest 
HDL-C quintile (Q5 ≥55 mg/dL) had a lower risk of 
major cardiovascular events than patients in the low-
est HDL-C quintile (Q1 <37 mg/dL). Combination 
therapy may be necessary to address multiple lipid tar-
gets (LDL-C, non-HDL-C, HDL-C, and triglycer-
ides). Among 57 patients treated with extended release 
(eR) niacin/statin for 24 months, there was a signifi-
cant regression in carotid iMt (-0.041 mm; P<0.001 
vs. placebo/statin). ARbiteR trial provided addi-
tional evidence to support the promise of long-term 
combination therapy in reducing cardiovascular risk. 
when eR niacin was added to statin therapy, there 
was a significant regression in atherosclerosis as mea-
sured by carotid iMt after both 12 and 24 months of 
treatment. in patients with diabetes or the metabolic 
syndrome, there was also a significant regression in 
carotid iMt (-0.046 mm; P<0.001 vs. placebo/statin) 
with eR niacin/statin after 12-24 months of treat-
ment versus statin monotherapy. Adding niacin or a 
fibrate to a statin is a therapeutic option that should 
be considered. As monotherapy agents, fibrates and 
niacin have been demonstrated to alter several lipid 
parameters and reduce cardiovascular events. niacin 
appears to exert the greatest beneficial effects on the 
widest range of lipoprotein abnormalities. niacin/sta-
tin combination therapy may slow down atheroscle-
rosis progression in CHD patients and reduce residual 
cardiovascular risk. niacin is the most effective agent 
for raising HDL-C levels, and eR niacin/statin combi-
nation therapy may promote the cost-effective achieve-
ment of optimal lipid values23. patients with CHD re-
ceiving long-term statin therapy and with LDL-C level 
under 100 mg/dL and HDL-C level under 50 mg/dL 
for men or 55 mg/dL for women, were randomly as-
signed to receive eR niacin (2000 mg/d) or ezetimibe 
(10 mg/d). The primary end point was between-group 
difference in the change from baseline in the mean 
common carotid iMt after 14 months. The mean 
HDL-C level in the niacin group increased by 18.4% 
over 14-months, to 50 mg/dL, and the mean LDL-C 
level in the ezetimibe group decreased by 19.2%, to 66 
mg/dL. niacin therapy significantly reduced LDL-C 
and triglyceride levels; ezetimibe reduced the HDL 
cholesterol and triglyceride levels. As compared with 
ezetimibe, niacin had greater efficacy regarding the 
change in the mean carotid iMt over 14 months, lead-
ing to significant reduction of both mean and maximal 
carotid iMt. paradoxically, greater reductions in the 
LDL-C level in association with ezetimibe were sig-
nificantly associated with an increase in carotid iMt. 
The incidence of major cardiovascular events was lower 
in the niacin group than in the ezetimibe group (1% vs. 
5%; P=0.04 by χ2-test)24.
Non-pharmacological Control of Plasma Cholesterol 
Levels
Reviewing studies on chocolate and stroke involv-
ing 44,489 subjects taking one serving of chocolate per 
week showed the subjects that consumed chocolate to 
be less likely to have a stroke than those that ate no 
chocolate; the observed stroke risk reduction was 22%. 
people who consumed 50 g of chocolate once a week 
were by 46% less likely to die from stroke than people 
who did not eat chocolate25. Consumption of choco-
late has been often hypothesized to reduce the risk of 
cardiovascular disease (CVD) due to chocolate’s high 
levels of stearic acid and antioxidant flavonoids. De-
bate still lingers regarding the true overall long term 
beneficial cardiovascular effects of chocolate. Review 
of the english-language MeDLine publications 
for experimental, observational, and clinical studies 
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of relations between cocoa, cacao, chocolate, stearic 
acid, flavonoids (including flavonols, flavanols, cat-
echins, epicatechins, and procynadins) and the risk of 
CVD (coronary heart disease, stroke) has shown that 
cocoa and chocolate may exert beneficial effects on 
cardiovascular risk via effects on lowering blood pres-
sure, anti-inflammation, anti-platelet function, higher 
HDL, and decreased LDL oxidation. Flavonoid con-
tent of chocolate may reduce the risk of cardiovascular 
mortality. Updated meta-analysis indicates that the 
intake of flavonoids may lower the risk of CHD mor-
tality, RR=0.81 (95% Ci: 0.71-0.92). Multiple lines of 
evidence from laboratory experiments and randomized 
trials suggest that stearic acid may be neutral, while 
flavonoids are likely to be protective against CHD 
mortality26. Regular aerobic physical activity generally 
induces an increase in plasma HDL-C and a decrease 
in plasma triglyceride levels. The effect on total and 
LDL-C is inconsistent and generally modest. This ef-
fect is dose-dependent and the efficacy threshold is set 
at 1500 kcal/week (equivalent to about 24 km of brisk 
walking or jogging per week). Aerobic physical activ-
ity such as walking, jogging, cycling or swimming, 
with total energy expenditure of 1500-2200 kcal/
week (which corresponds to about 24-32 km of brisk 
walking or jogging per week) may increase plasma 
HDL-C levels by 3.5-6 mg/dL and lower plasma trig-
lyceride levels by 7-20 mg/dL. Another 16 km/week 
would trigger an additional 3 mg/dL increase in plas-
ma HDL-C levels and an additional 3-8 mg/dL drop 
in plasma triglyceride concentrations27. interventions 
on other macro- and micronutrients have shown that 
ethanol consumption at doses that may be regarded 
as ‘moderate’ (30-40 g/day in men and 15-25 g/day in 
women) is associated with significantly higher HDL 
cholesterol levels than those found in non-drinkers. 
This effect is seen on both main HDL subfractions 
(HDL2 and HDL3) and may be directly elicited by 
ethanol through increased synthesis of apoA1, the 
major apolipoprotein present in HDL. High ethanol 
intake may sometimes increase plasma triglyceride 
levels, in particular in subjects already hypertriglyc-
eridemic at baseline, but on an average the effect of 
moderate ethanol doses on plasma triglyceride levels 
is not significant. The action of ethanol on HDL lipo-
proteins may account for about half of the reduction 
in coronary and cardiovascular risk associated with 
moderate ethanol consumption in observational stud-
ies27-30. improvements in HDL-C and plasma triglyc-
eride levels tend to be greater in overweight or obese 
subjects on low carbohydrate diet, whereas changes 
in LDL-C levels were more favorable in subjects on 
low-fat diets. in most available studies, body weight 
control can reduce significantly, albeit not dramati-
cally, plasma total and LDL-C levels, especially in 
obese subjects. A decline in triglycerides is usually ob-
served; HDL-C levels tend to rise on sustained weight 
loss27,31. incorporation of food products that contain 2 
g of phytosterols into the diet reduces plasma total and 
LDL-C levels by about 10% without significant ef-
fects on plasma HDL-C and triglycerides. Their con-
sumption should be linked to the principal meal and 
be continued for a long time27. including 25 g of soy 
protein in the diet as partial replacement for animal 
protein reduces plasma total and LDL-C concentra-
tions. The beneficial effects are proportionally greater 
in subjects with hypercholesterolemia; no significant 
effects are observed on HDL-C and plasma triglycer-
ide levels. The most effective cholesterol-lowering soy 
component is almost certainly protein, whereas isofla-
vones do not appear to contribute significantly to the 
effects on lipid metabolism. The cholesterol-lowering 
effect may be attributable to the ability of soy protein 
to up-regulate the expression of apo-b receptors27,32,33. 
Absorbable dietary carbohydrates do not play a major 
role in the control of total and plasma LDL choles-
terol levels, even though they can reduce the levels of 
these when they replace hypercholesterolemic fat, i.e. 
saturated and trans-fatty acids. on the other hand, 
low-gi foods may help ameliorate, although to a lim-
ited extent, plasma HDL cholesterol levels and reduce 
plasma triglyceride levels. A daily fiber intake of 25-
30 g may play a significant hypocholesterolemic role; 
soluble and gel-forming fiber is more effective than 
non-soluble fiber, and increasing its intake by 5 g/day 
can reduce total and plasma LDL cholesterol levels27.
Dietary Fatty Acids and Cholesterolemia
when isocalorically substituted for nutrients with 
neutral effects on cholesterolemia (such as carbohy-
drates), saturated and trans-fatty acids tend to increase 
total and plasma LDL cholesterol levels. polyunsatu-
rated, cis-fatty acids (those of the n-6 series such as 
linoleic acid) induce opposite effects. Monounsatu-
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rates, such as oleic acid, also reduce total and plasma 
LDL cholesterol levels, although to a lesser extent 
than n-6 polyunsaturates. The effects of fatty acids 
on plasma HDL cholesterol levels include an increase 
after saturate intake; an increase (to a lesser degree) 
after monounsaturate consumption; no change after 
polyunsaturates; and a decrease after trans ingestion. 
A lipid intake of 30%-35% of total calories is prob-
ably adequate to control total and plasma LDL cho-
lesterol; it is advisable to use mainly extra virgin olive 
oil as dietary fat of choice, even though its effects on 
total and plasma LDL cholesterol levels are modest. 
saturate intake should be limited to 7%-10%, while 
trans intake should be limited to those from dairy 
products only. The use of seed oils rich in n-6 poly-
unsaturates improves total and plasma LDL choles-
terol levels; polyunsaturates can contribute to up to 
7%-10% of total calories, including 1% of n-3 polyun-
saturates (which do not modify total and plasma LDL 
cholesterol levels)27,34. The most recent evidence puts 
a new perspective on the role of dietary cholesterol 
in cholesterolemia management. even if it may seem 
advisable not to exceed daily cholesterol intake of 300 
mg, it is unwise to reduce dramatically or eliminate 
cholesterol-rich foods such as eggs27.
Treatment of Lipid Abnormalities
The treatment of lipid abnormalities for primary 
prevention of CHD should be undertaken after global 
risk assessment in the individual patient. Family his-
tory, age, sex, blood pressure and presence of diabetes, 
as well as specific lipid abnormalities such as elevated 
LDL-C or low HDL-C should all be considered. 
Drug therapy should be considered in patients with 
elevated LDL-C and at least two additional risk fac-
tors. in primary prevention, when HDL-C is below 
average and other risk factors are present, a statin 
added to non-pharmacological therapy appears to be 
an appropriate choice, with a goal of 130 mg/dL (3.36 
mmol/L) or lower. based on the Veterans Affairs Co-
operative studies program High-Density Lipoprotein 
Cholesterol intervention trial, fibrate therapy may be 
appropriate in men with manifest coronary disease 
with isolated low HDL-C. The target for LDL-C 
lowering should be a level below 100 mg/dL (<2.59 
mmol/L). if HDL-C remains low, with or without 
high triglyceride levels, a fibrate or niacin may be add-
ed; however, the risks of such combinations, especially 
myopathy, should be considered35- 37.
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sažetak
niZAk HDL koLesteRoL kAo MogUći ČiMbenik RiZikA ZA MoŽDAni UDAR
V. Demarin, M. Lisak, S. Morović i T. Čengić
novija istraživanja ukazuju da nizak HDL kolesterol može pogoršati aterosklerotski proces, pospješiti upalu i progre-
siju bolesti od subkliničke lezije do kliničkog događaja. Debljina stijenke karotidne arterije (engl. intima-media thickness, 
iMt) je prepoznata kao pokazatelj rane ateroskleroze i predskazatelj budućih vaskularnih događaja. između lipidnih 
frakcija LDL ima najveću povezanost s karotidnim plakom. kumulativni učinak postizanja optimalnih vrijednosti LDL i 
HDL kolesterola, triglicerida i krvnog tlaka rezultira smanjenjem rizika od ponovljenog moždanog udara i kardiovasku-
larnih događaja. Zaštitni učinak povišenog HDL se održava pri niskim vrijednostima LDL. studije su pokazale trend 
prema povećanom riziku od moždanog udara pri niskim vrijednostima HDL te da je HDL važan modificirajući rizični 
čimbenik za moždani udar. U bolesnika s novijim moždanim udarom ili prolaznim ishemijskim napadajem (engl. transient 
ischemic attack, tiA) bez koronarne bolesti srca samo su niske bazične vrijednosti HDL su predskazatelj rizika za ponov-
ljeni moždani udar. Značajan ostatni kardiovaskularni rizik zaostaje u bolesnika koji su se liječili statinima, i to zbog povi-
šenih triglicerida i niskog HDL, iako su vrijednosti LDL dobro kontrolirane. niacin značajno povećava HDL i smanjuje 
kardiovaskularni rizik. kombinacija niacina i statina usporava napredovanje ateroskleroze, smanjuje ostatni kardiovasku-
larni rizik i rizik od moždanog udara. nefarmakološka kontrola serumskih lipida uključuje redovitu tjelesnu aktivnost i 
promjenu prehrambenih navika. U primarnoj prevenciji kada je HDL ispod prosječnih vrijednosti i uz prisutnost ostalih 
čimbenika rizika statini se mogu dodati nefarmakološkoj terapiji. terapija fibratima može biti prikladna u muškaraca s 
manifestnom koronarnom bolešću srca i izoliranim niskim vrijednostima HDL. Ako zaostanu niske vrijednosti HDL s 
povišenim trigliceridima ili bez njih, tada se u terapiju može dodati fibrati ili niacin. 
ključne riječi: Moždani infarkt – krv; Moždani infarkt – dijagnostika; Moždani infarkt – čimbenici rizika; Kolesterol – krv; 
Kolesterol, HDL – metabolizam; Ateroskleroza – dijagnostika; Ateroskleroza – patologija; Ateroskleroza - terapija

